

# Effect of heartfulness meditation on mental health and gene expression

<b>Submission date</b> 30/03/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 06/04/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 17/12/2024	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Stress is described by the National Institute of Mental Health as the brain's response to any demand. The current COVID-19 pandemic has heightened the anxiety and stress of many people. Medical students, paramedical students, allied health care students, and pharmacy students have a high degree of stress and burnout, and training physicians appear to be especially prone due to the number of hours spent at work each week, the large body of clinical knowledge to master, and the challenges of balancing work and home life. In addition, changes in stress levels correspond to changes in gene expression and even changes within the brain. Despite the potentially serious consequences of stress and burnout, there are few interventions designed to combat this problem in the medical student population.

This study will investigate whether a 12-week Heartfulness meditation program is associated with improvements in stress, anxiety levels, and depression symptoms in participants. The intervention chosen for this study is meditation with the guidance of a Heartfulness Meditation certified trainer who facilitates meditation with yogic energy, pranahuti. Heartfulness meditation is a simple heart-based meditation system aimed at attaining a balanced state of existence that has been shown to improve burnout, stress, and anxiety.

### Who can participate?

Medical students, paramedical students, allied health care students, and pharmacy students aged over 18 years

### What does the study involve?

Participants will be randomly allocated into the meditation group or the control group. Electronic copies of the assessment tools will be distributed and collected by the investigators. An education and consent session will be set up before the study. Willing participants will attend a talk on Heartfulness meditation and the study detailing the aspects of Heartfulness meditation and what to expect throughout the study and the opportunity to ask any questions. Anyone who agrees to participate in the study, and who signs the consent form, will be asked to fill out the demographics form. They will also be given a practice information sheet to take home.

The control group will receive no specific intervention. For the meditation group the Heartfulness meditation sessions will be available daily for 12 weeks. Participants are asked to

attend daily Heartfulness meditation sessions conducted by Heartfulness trainers. The participants will be given guided relaxation, the instructions of which would involve progressively relaxing the body from the toes to the top of their head followed by gently resting their attention on the idea of a source of light within their hearts. This is to be done in a gentle and natural way. If their attention drifts, they will be asked to gently redirect their attention toward their hearts. The session duration will be about 30 minutes each day. The participants will also be given an audio link for rejuvenation in the evening and relaxation prior to sleep. At week 0, participants will fill out the forms and undergo tests. Participants will be given a Heartfulness meditation log sheet to assess their practice every week. Blood samples will be collected at weeks 0 and 12 respectively in both groups and analyzed.

What are the possible benefits and risks of participating?

Benefits include possible improved mental well-being through learning meditation techniques. Some of the participants may have limited endurance and decreased strength related to their health conditions. Some may also have concurrent medical problems such as joint pains, or other challenges. Participants receive written and verbal instructions to never do anything that they feel is dangerous or painful to them. Medical aid is available in the hospitals affiliated with the medical colleges.

In the practice of Heartfulness meditation, although calmness is induced, there can also be the experience of unwanted emotions and thoughts arising and passing. If the participant is unable to continue meditation due to this, they may open their eyes briefly, take a slow deep breath, and then close their eyes to continue to meditate, or alternatively, they may leave if they desire to. There may also be bodily discomfort through sitting for a prolonged period. To address this, participants may change their posture to continue meditation. The recognition of this is a part of the long-term benefit of the course, but it can be upsetting or uncomfortable in the short term. Participants have their first experience of the technique in the supportive atmosphere of the classroom and are taught what to expect and how to cope with the experience as it unfolds. They also have contact information from the trainer and participants may call or email the trainer with any questions or concerns.

Where is the study run from?

Hospital for Mental Health, Ahmedabad, Gujarat (India)

When is the study starting and how long is it expected to run for?

January 2021 to January 2024

Who is funding the study?

1. Gujarat Industries Power Company Ltd (India)
2. Hirabhai Ashabhai Charitable Trust (India)

Who is the main contact?

1. Dr Ajay Chauhan, drajaypc@yahoo.com
2. Dr Jay Thimmapuram, jthimmapuram@wellspring.org

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Jayaram Thimmapuram

## Contact details

2780 Meadow Cross Way  
York  
United States of America  
17402  
+1 (0)7174956027  
jthimmapuram@wellspan.org

## Additional identifiers

### Protocol serial number

No.Ethics/Approval/01/2022

## Study information

### Scientific Title

Effect of mindfulness meditation on stress, anxiety, biomarkers and gene expression profile

### Study objectives

Current study hypothesis as of 05/01/2023:

The practice of mindfulness will be associated with a reduction in stress and anxiety along with changes in biomarkers, and gene expression profile.

Previous study hypothesis:

The practice of mindfulness will be associated with a reduction in stress and anxiety along with changes in biomarkers, gene expression profile, and brain fMRI corresponding to improved mental wellbeing.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 17/02/2022, Ethics Committee, Hospital for Mental Health Ahmedabad (Ahmedabad, 380004, India; +91 (0)79 25624583; ethicshmha@gmail.com), ref: Ethics/Approval/1/12022

### Study design

Prospective randomized single-center controlled study

### Primary study design

Interventional

### Study type(s)

Quality of life

### Health condition(s) or problem(s) studied

Stress and anxiety in healthy volunteers

### Interventions

Current interventions as of 05/01/2023:

Participants will be computer randomized to a Heartfulness meditation arm or a control arm with no specific intervention. The intervention includes daily guided Heartfulness meditation through a certified trainer for 12 weeks. Depression Anxiety Stress Scale (DASS-21) will be administered prior to the study and at the end of 12 weeks. Gene expression profile, and biomarkers will be done prior to the study and at the end of 12 weeks.

Previous interventions:

Participants will be computer randomized to a Heartfulness meditation arm or a control arm with no specific intervention. The intervention includes daily guided Heartfulness meditation through a certified trainer for 12 weeks. Perceived stress scale (PSS), Depression Anxiety Stress Scale (DASS-21) and impostor phenomenon scales will be administered prior to the study and at the end of 12 weeks. Gene expression profile, biomarkers and an fMRI brain scan will be done prior to the study and at the end of 12 weeks.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Current primary outcome measures as of 05/01/2023:

1. Depression, anxiety and stress measured with the Depression Anxiety Stress Scale (DASS-21) prior to the study and at the end of 12 weeks
2. Biomarkers measured using serological test prior to the study and at the end of 12 weeks
3. Gene expression profile including transcriptome analysis using mRNA sequencing prior to the study and at the end of 12 weeks

Previous primary outcome measures:

1. Stress measured with the perceived stress scale (PSS) prior to the study and at the end of 12 weeks
2. Anxiety measured with the Depression Anxiety Stress Scale (DASS-21) prior to the study and at the end of 12 weeks
3. Impostor syndrome measured using the Impostor Syndrome Scale prior to the study and at the end of 12 weeks
4. Brain changes measured using functional magnetic resonance imaging (fMRI) prior to the study and at the end of 12 weeks
5. Biomarkers measured using serological test prior to the study and at the end of 12 weeks
6. Gene expression profile including NFkB (Nuclear Factor kappa B) transcriptome analysis using mRNA sequencing prior to the study and at the end of 12 weeks

## **Key secondary outcome(s)**

Current secondary outcome measures as of 05/01/2023:

There are no secondary outcome measures

Previous secondary outcome measures:

Qualitative experience gathered using interviews at the end of the study

## **Completion date**

01/01/2024

## **Eligibility**

**Key inclusion criteria**

1. Adults above 18 years of age
2. Those who give consent for the study

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

78

**Key exclusion criteria**

1. Individuals less than 18 years of age
2. Active suicidal ideation, current or past diagnoses of manic-depressive disorders, post-traumatic stress disorder, psychotic disorders or any other psychiatric conditions requiring treatment
3. Individuals with claustrophobia, metal in the body, history of head injury, and current use of psychiatric medications
4. Those who don't give consent for the study

**Date of first enrolment**

22/03/2022

**Date of final enrolment**

24/04/2022

**Locations****Countries of recruitment**

India

**Study participating centre**

**Hospital for Mental Health - Gujarat Institute of Mental Health**

Bhadreshwar Society

Kazipur Dariyapur

Ahmedabad

India

380004

# Sponsor information

## Organisation

Gujarat Industries Power Company Ltd

# Funder(s)

## Funder type

Government

## Funder Name

Gujarat Industries Power Company Ltd

## Funder Name

Hirabhai Ashabhai Charitable Trust

# Results and Publications

## Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		16/12/2024	17/12/2024	Yes	No